Clinical TrialSingle-armKetamineCompleted

Low dose oral ketamine treatment on post-traumatic stress disorder (PTSD) (OKTOP): open-label pilot study

Ask Blossom about this trial
Target Enrollment
25 participants
Study Type
Design
Non-randomized

Study Protocol

Preparation

sessions

Dosing

6 sessions

Integration

sessions

Study Arms & Interventions

Low-dose oral ketamine

experimental

Open-label low-dose oral ketamine once weekly for six weeks, titrated upward.

Interventions

  • Ketamine
    via Oral• once weekly for six weeks• 6 doses total

    Paper describes low-dose oral ketamine in a titrating-up manner; exact dose schedule is in the primary OKTOP report, not this biomarker paper.

Study Details

  • Status
    Completed
  • Design
    Non-randomized
  • Target Enrollment25 participants
  • Compound
    Ketamine

Related Publications

Open AccessindividualSecondary analysis

Blood biomarker changes and relationships after low dose oral ketamine treatment for post-traumatic stress disorder (PTSD)

This open-label trial (n=25) found that six weeks of low-dose oral ketamine treatment for PTSD was associated with small but significant decreases in both BDNF and VEGF-A blood biomarkers, which were positively correlated with each other, suggesting these two proteins may interact as part of the biological mechanism behind ketamine's effects on PTSD symptoms.

Published
Journal
Psychopharmacology
Authors
Quigley, B. L., Orr, E., Kafka, S., Hajishafiee, M., Bouças, A. P., Wellington, N., Dutton, M., Jones, M., Randall, F., Lagopoulos, J., Can, A. T., Hermens, D. F.